{"id":"dobutamine-hydrochloride","rwe":[{"pmid":"41588817","year":"2026","title":"In Vitro Effects of Liquid Cardiac Drugs on Human Catalase Enzyme.","finding":"","journal":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","studyType":"Clinical Study"},{"pmid":"40490826","year":"2025","title":"Repurposing of an inotropic drug dobutamine to enhance the production of human hematopoietic stem cells from human induced pluripotent stem cells.","finding":"","journal":"Stem cell research & therapy","studyType":"Clinical Study"},{"pmid":"39426281","year":"2025","title":"Rapid detection of drugs in blood using \"molecular hook\" surface-enhanced Raman spectroscopy and artificial intelligence technology for clinical applications.","finding":"","journal":"Biosensors & bioelectronics","studyType":"Clinical Study"},{"pmid":"36328453","year":"2022","title":"[Chemical Stability after Mixing Continuous Infusion Drugs Used to Treat Cardiogenic Shock].","finding":"","journal":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","studyType":"Clinical Study"},{"pmid":"34337647","year":"2021","title":"Characterization of β-adrenergic receptors in bovine intramuscular and subcutaneous adipose tissue: comparison of lubabegron fumarate with β-adrenergic receptor agonists and antagonists.","finding":"","journal":"Journal of animal science","studyType":"Clinical Study"}],"_fda":{"id":"34c787c1-46f7-4264-951d-c88a34dca533","set_id":"6b17b98b-e06d-42ed-925f-69aa2699dead","openfda":{"unii":["0WR771DJXV"],"route":["INTRAVENOUS"],"rxcui":["309985","309986","309987"],"spl_id":["34c787c1-46f7-4264-951d-c88a34dca533"],"brand_name":["Dobutamine Hydrochloride in Dextrose"],"spl_set_id":["6b17b98b-e06d-42ed-925f-69aa2699dead"],"package_ndc":["0338-1073-02","0338-1075-02","0338-1077-02"],"product_ndc":["0338-1073","0338-1075","0338-1077"],"generic_name":["DOBUTAMINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DOBUTAMINE HYDROCHLORIDE"],"manufacturer_name":["Baxter Healthcare Corporation"],"application_number":["NDA020255"],"is_original_packager":[true]},"version":"23","warnings":["WARNINGS Increase in Heart Rate or Blood Pressure Dobutamine Hydrochloride in 5% Dextrose Injection may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Approximately 10% of adult patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50-mm Hg or greater increase in systolic pressure. Usually, reduction of dosage reverses these effects. Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. Patients with preexisting hypertension appear to face an increased risk of developing an exaggerated pressor response. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with Dobutamine in D 5 W. Ectopic Activity Dobutamine Hydrochloride in 5% Dextrose Injection may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia. Hypersensitivity Reactions suggestive of hypersensitivity associated with administration of dobutamine including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally. Dobutamine Hydrochloride in 5% Dextrose Injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Solutions containing dextrose should not be administered through the same administration set as blood, as this may result in pseudoagglutination or hemolysis. The intravenous administration of solutions may cause fluid overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration of the injections. Excess administration of potassium-free solutions may result in significant hypokalemia."],"pregnancy":["Pregnancy Reproduction studies performed in rats and rabbits have revealed no evidence of harm to the fetus due to dobutamine. The drug, however, has not been administered to pregnant women and should be used only when the expected benefits clearly outweigh the potential risks to the fetus."],"overdosage":["OVERDOSAGE Overdoses of dobutamine have been reported rarely. The following is provided to serve as a guide if such an overdose is encountered. Signs and Symptoms Toxicity from dobutamine is usually due to excessive cardiac beta-receptor stimulation. The duration of action of dobutamine is generally short (T1/2 = two minutes) because it is rapidly metabolized by catechol-O-methyltransferase. The symptoms of toxicity may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath, and anginal and nonspecific chest pain. The positive inotropic and chronotropic effects of dobutamine on the myocardium may cause hypertension, tachyarrhythmias, myocardial ischemia, and ventricular fibrillation. Hypotension may result from vasodilation. If the product is ingested, unpredictable absorption may occur from the mouth and the gastrointestinal tract. Treatment To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient. The initial actions to be taken in a dobutamine overdose are discontinuing administration, establishing an airway, and ensuring oxygenation and ventilation. Resuscitative measures should be initiated promptly. Severe ventricular tachyarrhythmias may be successfully treated with propranolol or lidocaine. Hypertension usually responds to a reduction in dose or discontinuation of therapy. Protect the patient’s airway and support ventilation and perfusion. If needed, meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal. Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of dobutamine."],"description":["DESCRIPTION Dobutamine Hydrochloride in 5% Dextrose Injection is a sterile, nonpyrogenic solution of Dobutamine Hydrochloride, USP and Dextrose, USP in Water for Injection, USP. Dobutamine hydrochloride is chemically designated as (±)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride. It is a synthetic catecholamine. Dextrose Hydrous, USP is chemically designated as D-Glucopyranose monohydrate. Structural formulas are shown below: Dobutamine Hydrochloride, USP (D-Glucopyranose monohydrate) Dextrose Hydrous, USP Dobutamine Hydrochloride in 5% Dextrose Injection is intended for intravenous use only. It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide and/or hydrochloric acid. Sodium bisulfite is added as a stabilizer. The solution is intended for single use only. When smaller doses are required, the unused portion should be discarded. Composition, osmolarity, pH and caloric content are given in Table 1. Table 1. Composition Approximately 5 mEq/L sodium bisulfite is added as a stabilizer. Dobutamine Hydrochloride in 5% Dextrose Injection. Dobutamine (mg/Container) Dobutamine (mcg/mL) Dextrose Hydrous, USP (g/L) Osmolarity (mOsmol/L) (calc) Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (≥ 600 mOsmol/L) may cause vein damage. pH kcal/L 250 mg/250 mL 1000 50 259 3.5 (2.5 to 5.5) 170 500 mg/250 mL 2000 50 266 3.5 (2.5 to 5.5) 170 1000 mg/250 mL 4000 50 280 3.5 (2.5 to 5.5) 170 This Viaflex Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 2207 Plastic). Viaflex containers, including Viaflex Plus containers, are made of flexible plastic and are for parenteral use. Viaflex Plus on the container indicates the presence of a drug additive in a drug vehicle. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies. Dobutamine Hydrochloride Structural Formula D-Glucopyranose monohydrate - Dextrose Hydrous Structural Formula"],"precautions":["PRECAUTIONS General During the administration of Dobutamine Hydrochloride in 5% Dextrose Injection, as with any adrenergic agent, ECG and blood pressure should be continuously monitored. In addition, pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid in the safe and effective infusion of dobutamine. Hypovolemia should be corrected with suitable volume expanders before treatment with dobutamine is instituted. Animal studies indicate that dobutamine may be ineffective if the patient has recently received a beta-blocking drug. In such a case, the peripheral vascular resistance may increase. No improvement may be observed in the presence of marked mechanical obstruction, such as severe valvular aortic stenosis. Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus. Do not administer unless solution is clear and seal is intact. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. Usage Following Acute Myocardial Infarction Clinical experience with dobutamine following myocardial infarction has been insufficient to establish the safety of the drug for this use. There is concern that any agent that increases contractile force and heart rate may increase the size of an infarction by intensifying ischemia, but it is not known whether dobutamine does so. Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to evaluate the carcinogenic or mutagenic potential of dobutamine or the potential of the drug to affect fertility adversely have not been performed. Pregnancy Reproduction studies performed in rats and rabbits have revealed no evidence of harm to the fetus due to dobutamine. The drug, however, has not been administered to pregnant women and should be used only when the expected benefits clearly outweigh the potential risks to the fetus. Pediatric Use Dobutamine has been shown to increase cardiac output and systemic pressure in pediatric patients of every age group. In premature neonates, however, dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia, and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine. Geriatric Use Clinical studies of dobutamine injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy."],"how_supplied":["HOW SUPPLIED Dobutamine Hydrochloride in 5% Dextrose Injection in Viaflex Plus plastic containers is available as follows: 2B0791 Dobutamine 250 mg/250 mL NDC 0338-1073-02 2B0792 Dobutamine 500 mg/250 mL NDC 0338-1075-02 2B0793 Dobutamine 1000 mg/250 mL NDC 0338-1077-02 Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product. Directions for use of VIAFLEX PLUS Plastic Container The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. A sulfur dioxide odor may occur upon removal of the product from the overwrap container. The sulfur dioxide odor from Dobutamine Injection does not pose risk to the clinician or patient using the product. To open Tear overwrap down side at notch and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. Preparation for Administration Visually inspect the container. If the administration port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Caution: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed. 1. Suspend container from eyelet support. 2. Remove plastic protector from administration port at bottom of container. 3. Attach administration set. Refer to complete directions accompanying set. Table 2. Infusion Rate (mL/hr) of Dobutamine Hydrochloride in 5% Dextrose Injection. 1000 mcg/mL Patient's Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110 0.5 0.15 0.30 0.60 0.90 1.2 1.5 1.8 2.1 2.4 2.7 3.0 3.3 1 0.30 0.60 1.2 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 6.6 2.5 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17 5 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33 7.5 2.3 4.5 9.0 14 18 23 27 32 36 41 45 50 10 3.0 6.0 12 18 24 30 36 42 48 54 60 66 12.5 3.8 7.5 15 23 30 38 45 53 60 68 75 83 15 4.5 9.0 18 27 36 45 54 63 72 81 90 99 17.5 5.3 11 21 32 42 53 63 74 84 95 105 116 20 6.0 12 24 36 48 60 72 84 96 108 120 132 2000 mcg/mL Patient's Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110 0.5 0.08 0.15 0.30 0.45 0.60 0.75 0.90 1.1 1.2 1.4 1.5 1.7 1 0.15 0.30 0.60 0.90 1.2 1.5 1.8 2.1 2.4 2.7 3.0 3.3 2.5 0.38 0.75 1.5 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 8.3 5 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17 7.5 1.1 2.3 4.5 6.8 9.0 11 14 16 18 20 23 25 10 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33 12.5 1.9 3.8 7.5 11 15 19 23 26 30 34 38 41 15 2.3 4.5 9.0 14 18 23 27 32 36 41 45 50 17.5 2.6 5.3 11 16 21 26 32 37 42 47 53 58 20 3.0 6.0 12 18 24 30 36 42 48 54 60 66 4000 mcg/mL Patient's Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110 0.5 0.04 0.08 0.15 0.23 0.30 0.38 0.45 0.53 0.60 0.68 0.75 0.83 1 0.08 0.15 0.30 0.45 0.60 0.75 0.90 1.1 1.2 1.4 1.5 1.7 2.5 0.19 0.38 0.75 1.1 1.5 1.9 2.3 2.6 3.0 3.4 3.8 4.1 5 0.38 0.75 1.5 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 8.3 7.5 0.56 1.1 2.3 3.4 4.5 5.6 6.8 7.9 9.0 10 11 12 10 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17 12.5 0.94 1.9 3.8 5.6 7.5 9.4 11 13 15 17 19 21 15 1.1 2.3 4.5 6.8 9.0 11 14 16 18 20 23 25 17.5 1.3 2.6 5.3 7.9 11 13 16 18 21 24 26 29 20 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33 Baxter, Viaflex and Viaflex Plus are trademarks of Baxter International Inc. or its subsidiaries. Baxter Healthcare Corporation Deerfield, IL 60015 USA Printed in USA 07-19-00-5947 Rev. September 2023"],"geriatric_use":["Geriatric Use Clinical studies of dobutamine injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy."],"pediatric_use":["Pediatric Use Dobutamine has been shown to increase cardiac output and systemic pressure in pediatric patients of every age group. In premature neonates, however, dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia, and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine."],"effective_time":"20230908","adverse_reactions":["ADVERSE REACTIONS Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity A 10 to 20-mm Hg increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (see WARNINGS regarding exaggerated chronotropic and pressor effects). Approximately 5% of adult patients have had increased premature ventricular beats during infusions. These effects are dose related. Hypotension Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. In rare cases, however, intervention may be required and reversibility may not be immediate. Stress Cardiomyopathy Stress cardiomyopathy has been reported with dobutamine in association with cardiac stress testing. Reactions at Sites of Intravenous Infusion Phlebitis has occasionally been reported. Local inflammatory changes have been described following inadvertent infiltration. Miscellaneous Uncommon Effects The following adverse effects have been reported in 1% to 3% of adult patients: nausea, headache, anginal pain, nonspecific chest pain, palpitations, and shortness of breath. Administration of dobutamine, like other catecholamines, has been associated with decreases in serum potassium concentrations, rarely to hypokalemic values."],"contraindications":["CONTRAINDICATIONS Dobutamine Hydrochloride in 5% Dextrose Injection is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products."],"description_table":["
Table 1. CompositionApproximately 5 mEq/L sodium bisulfite is added as a stabilizer. Dobutamine Hydrochloride in 5% Dextrose Injection.
Dobutamine (mg/Container)Dobutamine (mcg/mL)Dextrose Hydrous, USP (g/L)Osmolarity (mOsmol/L) (calc)Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (≥ 600 mOsmol/L) may cause vein damage.pHkcal/L
250 mg/250 mL 1000 50 259 3.5 (2.5 to 5.5) 170
500 mg/250 mL 2000 50 266 3.5 (2.5 to 5.5) 170
1000 mg/250 mL 4000 50 280 3.5 (2.5 to 5.5) 170
"],"drug_interactions":["Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone."],"how_supplied_table":["
2B0791Dobutamine 250 mg/250 mLNDC 0338-1073-02
2B0792Dobutamine 500 mg/250 mLNDC 0338-1075-02
2B0793Dobutamine 1000 mg/250 mLNDC 0338-1077-02
","
Table 2. Infusion Rate (mL/hr) of Dobutamine Hydrochloride in 5% Dextrose Injection.
1000 mcg/mL Patient's Weight (kg)
Drug Delivery Rate (mcg/kg/min)5 10 20 30 40 50 60 70 80 90 100 110
0.5 0.15 0.30 0.60 0.90 1.2 1.5 1.8 2.1 2.4 2.7 3.0 3.3
1 0.30 0.60 1.2 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 6.6
2.5 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17
5 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33
7.5 2.3 4.5 9.0 14 18 23 27 32 36 41 45 50
10 3.0 6.0 12 18 24 30 36 42 48 54 60 66
12.5 3.8 7.5 15 23 30 38 45 53 60 68 75 83
15 4.5 9.0 18 27 36 45 54 63 72 81 90 99
17.5 5.3 11 21 32 42 53 63 74 84 95 105 116
20 6.0 12 24 36 48 60 72 84 96 108 120 132
2000 mcg/mL Patient's Weight (kg)
Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110
0.5 0.08 0.15 0.30 0.45 0.60 0.75 0.90 1.1 1.2 1.4 1.5 1.7
1 0.15 0.30 0.60 0.90 1.2 1.5 1.8 2.1 2.4 2.7 3.0 3.3
2.5 0.38 0.75 1.5 2.3 3.0 3.84.5 5.3 6.0 6.8 7.5 8.3
5 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17
7.5 1.1 2.3 4.5 6.8 9.0 11 14 16 18 20 23 25
10 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33
12.5 1.9 3.8 7.5 1115 19 23 26 30 34 38 41
15 2.3 4.5 9.0 14 18 23 27 32 36 41 45 50
17.5 2.6 5.3 11 16 21 26 32 37 42 4753 58
20 3.0 6.0 12 18 24 30 36 42 48 54 60 66
4000 mcg/mL Patient's Weight (kg)
Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110
0.5 0.04 0.08 0.15 0.23 0.30 0.38 0.45 0.53 0.60 0.68 0.75 0.83
1 0.08 0.15 0.30 0.45 0.60 0.75 0.90 1.1 1.2 1.4 1.5 1.7
2.5 0.19 0.38 0.75 1.1 1.5 1.92.3 2.6 3.0 3.4 3.8 4.1
5 0.38 0.75 1.5 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 8.3
7.5 0.56 1.1 2.3 3.4 4.5 5.6 6.8 7.9 9.0 10 11 12
10 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17
12.5 0.94 1.9 3.8 5.6 7.5 9.4 11 13 15 17 19 21
15 1.1 2.3 4.5 6.89.0 11 14 16 18 20 23 25
17.5 1.3 2.6 5.3 7.9 11 13 16 18 21 24 26 29
20 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33
"],"general_precautions":["General During the administration of Dobutamine Hydrochloride in 5% Dextrose Injection, as with any adrenergic agent, ECG and blood pressure should be continuously monitored. In addition, pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid in the safe and effective infusion of dobutamine. Hypovolemia should be corrected with suitable volume expanders before treatment with dobutamine is instituted. Animal studies indicate that dobutamine may be ineffective if the patient has recently received a beta-blocking drug. In such a case, the peripheral vascular resistance may increase. No improvement may be observed in the presence of marked mechanical obstruction, such as severe valvular aortic stenosis. Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus. Do not administer unless solution is clear and seal is intact. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine. In animal studies, dobutamine produces less increase in heart rate and less decrease in peripheral vascular resistance for a given inotropic effect than does isoproterenol. In patients with depressed cardiac function, both dobutamine and isoproterenol increase the cardiac output to a similar degree. In the case of dobutamine, this increase is usually not accompanied by marked increases in heart rate (although tachycardia is occasionally observed), and the cardiac stroke volume is usually increased. In contrast, isoproterenol increases the cardiac index primarily by increasing the heart rate while stroke volume changes little or declines. Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation. Systemic vascular resistance is usually decreased with administration of dobutamine. Occasionally, minimum vasoconstriction has been observed. Most clinical experience with dobutamine is short-term - not more than several hours in duration. In the limited number of patients who were studied for 24, 48, and 72 hours, a persistent increase in cardiac output occurred in some, whereas output returned toward baseline values in others. The onset of action of dobutamine is within one to two minutes; however, as much as ten minutes may be required to obtain the peak effect of a particular infusion rate. The plasma half-life of dobutamine in humans is two minutes. The principal routes of metabolism are methylation of the catechol and conjugation. In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine. The 3-O-methyl derivative of dobutamine is inactive. Alteration of synaptic concentrations of catecholamines with either reserpine or tricyclic antidepressants does not alter the actions of dobutamine in animals, which indicates that the actions of dobutamine are not dependent on presynaptic mechanisms. The effective infusion rate of dobutamine varies widely from patient to patient, and titration is always necessary (see DOSAGE AND ADMINISTRATION ). At least in pediatric patients, dobutamine-induced increases in cardiac output and systemic pressure are generally seen, in any given patient, at lower infusion rates than those that cause substantial tachycardia (see PRECAUTIONS, Pediatric Use ). Dextrose provides a source of calories. Dextrose is readily metabolized, may decrease losses of body protein and nitrogen, promotes glycogen deposition and decreases or prevents ketosis if sufficient doses are provided."],"indications_and_usage":["INDICATIONS AND USAGE Dobutamine Hydrochloride in 5% Dextrose Injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Recommended Dosage Dobutamine Hydrochloride in 5% Dextrose Injection is administered intravenously through a suitable intravenous catheter or needle. A calibrated electronic infusion device is recommended for controlling the rate of flow in mL/hour or drops/minute. Infusion of dobutamine should be started at a low rate (0.5-1.0 mcg/kg/min) and titrated at intervals of a few minutes, guided by the patient’s response, including systemic blood pressure, urine flow, frequency of ectopic activity, heart rate, and (whenever possible) measurements of cardiac output, central venous pressure, and/or pulmonary capillary wedge pressure. In reported trials, the optimal infusion rates have varied from patient to patient, usually 2-20 mcg/kg/min but sometimes slightly outside of this range. On rare occasions, infusion rates up to 40 mcg/kg/min have been required to obtain the desired effect. Rates of infusion in mL/hour for dobutamine hydrochloride concentrations of 1,000, 2,000 and 4,000 mcg/mL are in Table 2. This container system may be inappropriate for the dosage requirements of pediatric patients under 30 kg. Other dosage forms may be more appropriate. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Dobutamine Hydrochloride in 5% Dextrose Injection solutions may exhibit a pink color that, if present, will increase with time. This color change is due to slight oxidation of the drug, but there is no significant loss of potency. The rate of administration and the duration of therapy should be adjusted according to the patient’s response, as determined by heart rate, presence of ectopic activity, blood pressure, urine flow, and, whenever possible, measurement of central venous or pulmonary wedge pressure and cardiac output. Do not add supplementary medications to Dobutamine Hydrochloride in 5% Dextrose Injection. Do not administer Dobutamine Hydrochloride in 5% Dextrose Injection simultaneously with solutions containing sodium bicarbonate or strong alkaline solutions."],"spl_product_data_elements":["Dobutamine Hydrochloride in Dextrose Dobutamine Hydrochloride DOBUTAMINE HYDROCHLORIDE DOBUTAMINE DEXTROSE MONOHYDRATE SODIUM BISULFITE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER Dobutamine Hydrochloride in Dextrose Dobutamine Hydrochloride DOBUTAMINE HYDROCHLORIDE DOBUTAMINE DEXTROSE MONOHYDRATE SODIUM BISULFITE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER Dobutamine Hydrochloride in Dextrose Dobutamine Hydrochloride DOBUTAMINE HYDROCHLORIDE DOBUTAMINE DEXTROSE MONOHYDRATE SODIUM BISULFITE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER"],"package_label_principal_display_panel":["Principal Display Panel - Packaging Labeling Container Label LOT EXP NDC 0338-1073-02 DOBUTamine Dobutamine Hydrochloride in 5% Dextrose Injection 250 mg per 250 mL (1,000 mcg/mL) 250 ml Sterile single dose container Each 100 mL contains Dobutamine HCl USP equivalent to 100 mg Dobutamine and 5 g Dextrose Hydrous USP 5 mEq/L Sodium Bisulfite added as a stabilizer pH 3.5 (2.5 to 5.5) Osmolarity 259 mOsmol/L (CALC) Usual Dosage See Insert Do not add supplementary medication Store in moisture and oxygen barrier overwrap at room temperature (77ºF or 25ºC) until ready to use Rx Only Baxter Logo USA 07-25-00-1609 2B0791 50 100 150 200 Container Label LOT EXP NDC 0338-1075-02 DOBUTamine Dobutamine Hydrochloride in 5% Dextrose Injection 500 mg per 250 mL (2,000 mcg/mL) 250 ml Sterile single dose container Each 100 mL contains Dobutamine HCl USP equivalent to 200 mg Dobutamine and 5 g Dextrose Hydrous USP 5 mEq/L Sodium Bisulfite added as a stabilizer pH 3.5 (2.5 to 5.5) Osmolarity 266 mOsmol/L (CALC) Usual Dosage See Insert Do not add supplementary medication Store in moisture and oxygen barrier overwrap at room temperature (77ºF or 25ºC) until ready to use Rx Only Baxter Logo USA 07-25-00-1610 2B0792 50 100 150 200 Container Label LOT EXP NDC 0338-1077-02 DOBUTamine Dobutamine Hydrochloride in 5% Dextrose Injection 1,000 mg per 250 mL (4,000 mcg/mL) 250 ml Sterile single dose container Each 100 mL contains Dobutamine HCl USP equivalent to 400 mg Dobutamine and 5 g Dextrose Hydrous USP 5 mEq/L Sodium Bisulfite added as a stabilizer pH 3.5 (2.5 to 5.5) Osmolarity 280 mOsmol/L (CALC) Usual Dosage See Insert Do not add supplementary medication Store in moisture and oxygen barrier overwrap at room temperature (77ºF or 25ºC) until ready to use Rx Only Baxter Logo USA 07-25-00-1611 2B0793 50 100 150 200 Representative Container Label 0338-1073-02 Dobutamine Hydrochloride Representative Container Label Representative Container Label NDC 0338-1077-02"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to evaluate the carcinogenic or mutagenic potential of dobutamine or the potential of the drug to affect fertility adversely have not been performed."]},"tags":[{"label":"beta-Adrenergic Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-1D adrenergic receptor","category":"target"},{"label":"ADRA1D","category":"gene"},{"label":"SLC6A3","category":"gene"},{"label":"SLC6A2","category":"gene"},{"label":"C01CA07","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Cardiac Decompensation","category":"indication"},{"label":"Cardiac Decompensation Post Cardiac Surgery","category":"indication"},{"label":"Cardiogenic shock","category":"indication"},{"label":"Decompensated cardiac failure","category":"indication"},{"label":"Organic Cardiac Disease","category":"indication"},{"label":"Stress echocardiography using dobutamine","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic beta-1 Receptor Agonists","category":"pharmacology"},{"label":"Adrenergic beta-Agonists","category":"pharmacology"},{"label":"Cardiotonic Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"}],"phase":"marketed","fdaNDC":[{"route":["INTRAVENOUS"],"labeler":"Baxter Healthcare Corporation","brandName":"Dobutamine Hydrochloride in Dextrose","packaging":[{"ndc":"0338-1075-02","description":"18 BAG in 1 CARTON (0338-1075-02) / 250 mL in 1 BAG","marketingStartDate":"19930927"}],"dosageForm":"INJECTION","genericName":"Dobutamine Hydrochloride","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DOBUTAMINE HYDROCHLORIDE","strength":"200 mg/100mL"}],"marketingCategory":"NDA"},{"route":["INTRAVENOUS"],"labeler":"Baxter Healthcare Corporation","brandName":"Dobutamine Hydrochloride in Dextrose","packaging":[{"ndc":"0338-1073-02","description":"18 BAG in 1 CARTON (0338-1073-02) / 250 mL in 1 BAG","marketingStartDate":"19930927"}],"dosageForm":"INJECTION","genericName":"Dobutamine Hydrochloride","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DOBUTAMINE HYDROCHLORIDE","strength":"100 mg/100mL"}],"marketingCategory":"NDA"},{"route":["INTRAVENOUS"],"labeler":"Baxter Healthcare Corporation","brandName":"Dobutamine Hydrochloride in Dextrose","packaging":[{"ndc":"0338-1077-02","description":"18 BAG in 1 CARTON (0338-1077-02) / 250 mL in 1 BAG","marketingStartDate":"19930927"}],"dosageForm":"INJECTION","genericName":"Dobutamine Hydrochloride","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DOBUTAMINE HYDROCHLORIDE","strength":"400 mg/100mL"}],"marketingCategory":"NDA"},{"route":["INTRAVENOUS"],"labeler":"HF Acquisition Co LLC, DBA HealthFirst","brandName":"DOBUTAMINE HYDROCHLORIDE","packaging":[{"ndc":"51662-1566-1","description":"250 mL in 1 BAG (51662-1566-1)","marketingStartDate":"20210710"}],"dosageForm":"INJECTION","genericName":"DOBUTAMINE HYDROCHLORIDE","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DOBUTAMINE HYDROCHLORIDE","strength":"100 mg/100mL"}],"marketingCategory":"NDA"},{"route":[],"labeler":"RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA","brandName":"","packaging":[{"ndc":"12711-4820-0","description":"25 kg in 1 DRUM (12711-4820-0)","marketingStartDate":"01-JAN-92"}],"dosageForm":"POWDER","genericName":"Dobutamine Hydrochloride","productType":"DRUG FOR FURTHER PROCESSING","activeIngredients":[{"name":"DOBUTAMINE HYDROCHLORIDE","strength":"25 kg/25kg"}],"marketingCategory":"DRUG FOR FURTHER PROCESSING"}],"safety":{"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"268 reports"},{"date":"","signal":"STRESS","source":"FDA FAERS","actionTaken":"140 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"126 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"114 reports"},{"date":"","signal":"MULTIPLE ORGAN DYSFUNCTION SYNDROME","source":"FDA FAERS","actionTaken":"108 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"106 reports"},{"date":"","signal":"CARDIOGENIC SHOCK","source":"FDA FAERS","actionTaken":"104 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"103 reports"},{"date":"","signal":"GENERAL PHYSICAL HEALTH DETERIORATION","source":"FDA FAERS","actionTaken":"101 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"100 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"96 reports"},{"date":"","signal":"VENTRICULAR FIBRILLATION","source":"FDA FAERS","actionTaken":"95 reports"},{"date":"","signal":"ASCITES","source":"FDA FAERS","actionTaken":"94 reports"},{"date":"","signal":"HYPONATRAEMIA","source":"FDA FAERS","actionTaken":"91 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"91 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"90 reports"},{"date":"","signal":"ABDOMINAL DISTENSION","source":"FDA FAERS","actionTaken":"88 reports"},{"date":"","signal":"APPENDICITIS","source":"FDA FAERS","actionTaken":"86 reports"},{"date":"","signal":"ATRIAL FIBRILLATION","source":"FDA FAERS","actionTaken":"86 reports"},{"date":"","signal":"APPENDICOLITH","source":"FDA FAERS","actionTaken":"85 reports"},{"date":"","signal":"INJURY","source":"FDA FAERS","actionTaken":"85 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"84 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"84 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"83 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"79 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"78 reports"},{"date":"","signal":"UNEVALUABLE EVENT","source":"FDA FAERS","actionTaken":"77 reports"},{"date":"","signal":"FEAR","source":"FDA FAERS","actionTaken":"73 reports"},{"date":"","signal":"BLOOD PHOSPHORUS INCREASED","source":"FDA FAERS","actionTaken":"70 reports"},{"date":"","signal":"SOMNOLENCE","source":"FDA FAERS","actionTaken":"69 reports"},{"date":"","signal":"EMOTIONAL DISTRESS","source":"FDA FAERS","actionTaken":"67 reports"},{"date":"","signal":"DRY MOUTH","source":"FDA FAERS","actionTaken":"65 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"62 reports"},{"date":"","signal":"MYASTHENIA GRAVIS","source":"FDA FAERS","actionTaken":"62 reports"},{"date":"","signal":"CARDIAC STRESS TEST ABNORMAL","source":"FDA FAERS","actionTaken":"60 reports"},{"date":"","signal":"BLOOD CHOLESTEROL INCREASED","source":"FDA FAERS","actionTaken":"57 reports"},{"date":"","signal":"BLOOD URIC ACID INCREASED","source":"FDA FAERS","actionTaken":"57 reports"},{"date":"","signal":"DIABETES MELLITUS","source":"FDA FAERS","actionTaken":"57 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"57 reports"},{"date":"","signal":"PULMONARY EMBOLISM","source":"FDA FAERS","actionTaken":"57 reports"},{"date":"","signal":"ANHEDONIA","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"BACTERIAL INFECTION","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"DRUG INTOLERANCE","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"RENAL IMPAIRMENT","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"SWELLING","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"THROMBOSIS","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"NEURALGIA","source":"FDA FAERS","actionTaken":"55 reports"},{"date":"","signal":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","source":"FDA FAERS","actionTaken":"54 reports"},{"date":"","signal":"INTENTIONAL PRODUCT MISUSE","source":"FDA FAERS","actionTaken":"54 reports"},{"date":"","signal":"RENAL INJURY","source":"FDA FAERS","actionTaken":"54 reports"}],"drugInteractions":[{"drug":"Digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, acetaminophen","severity":"None","mechanism":"","management":"","clinicalEffect":"No evidence of drug interactions in clinical studies"},{"drug":"Nitroprusside","severity":"Beneficial","mechanism":"","management":"","clinicalEffect":"Concomitant use results in higher cardiac output and usually lower pulmonary wedge pressure than either drug alone"}],"commonSideEffects":[{"effect":"Increased premature ventricular beats during infusions","drugRate":"5%","placeboRate":null},{"effect":"Nausea","drugRate":"1% to 3%","placeboRate":null},{"effect":"Headache","drugRate":"1% to 3%","placeboRate":null},{"effect":"Anginal pain","drugRate":"1% to 3%","placeboRate":null},{"effect":"Nonspecific chest pain","drugRate":"1% to 3%","placeboRate":null},{"effect":"Palpitations","drugRate":"1% to 3%","placeboRate":null},{"effect":"Shortness of breath","drugRate":"1% to 3%","placeboRate":null}],"contraindications":["Idiopathic hypertrophic subaortic stenosis","Previous manifestations of hypersensitivity to dobutamine","Known allergy to corn or corn products (due to dextrose component)"],"specialPopulations":{"Geriatric":"Geriatric Use Clinical studies of dobutamine injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or car","Pediatric":"Pediatric Use Dobutamine has been shown to increase cardiac output and systemic pressure in pediatric patients of every age group. In premature neonates, however, dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia, and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine.","Pregnancy":"Pregnancy Reproduction studies performed in rats and rabbits have revealed no evidence of harm to the fetus due to dobutamine. The drug, however, has not been administered to pregnant women and should be used only when the expected benefits clearly outweigh the potential risks to the fetus."},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:26:58.603421","_sources":{"fdaNDC":{"url":"","method":"api_direct","source":"FDA NDC Directory","rawText":"","confidence":1,"sourceType":"fda_ndc","retrievedAt":"2026-04-19T18:44:04.405271+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T18:44:19.057015+00:00"},"dailyMed":{"url":"","method":"api_direct","source":"DailyMed (NIH/NLM)","rawText":"","confidence":1,"sourceType":"dailymed","retrievedAt":"2026-04-19T18:44:05.184121+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"Haiku strategic summary","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:54:24.216098+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:25:13.796306+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200418/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T18:44:12.469706+00:00"},"overdosage":{"url":"","method":"deterministic","source":"FDA Label (overdosage)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:43:16.790585+00:00"},"howSupplied":{"url":"","method":"deterministic","source":"FDA Label (how_supplied)","rawText":"HOW SUPPLIED Dobutamine Hydrochloride in 5% Dextrose Injection in Viaflex Plus plastic containers is available as follows: 2B0791 Dobutamine 250 mg/250 mL NDC 0338-1073-02 2B0792 Dobutamine 500 mg/250 mL NDC 0338-1075-02 2B0793 Dobutamine 1000 mg/250 mL NDC 0338-1077-02 Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:43:02.671239+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:44:28.730752+00:00"},"drugDescription":{"url":"","method":"ai_extraction","source":"FDA Label (description)","aiModel":"featherless","rawText":"DESCRIPTION Dobutamine Hydrochloride in 5% Dextrose Injection is a sterile, nonpyrogenic solution of Dobutamine Hydrochloride, USP and Dextrose, USP in Water for Injection, USP. Dobutamine hydrochloride is chemically designated as (±)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride. It is a synthetic catecholamine. Dextrose Hydrous, USP is chemically designated as D-Glucopyranose monohydrate. Structural formulas are shown below: Dobutamine Hydrochloride, USP (D-","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:43:16.790480+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:25:13.796327+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T18:44:10.153031+00:00"},"faersTotalReports":{"url":"","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T18:44:09.657595+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T18:44:11.112695+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:44:28.730684+00:00"},"safety.safetySignals":{"url":"","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T18:44:06.019348+00:00"},"nonclinicalToxicology":{"url":"","method":"deterministic","source":"FDA Label (nonclinical_toxicology)","rawText":"Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to evaluate the carcinogenic or mutagenic potential of dobutamine or the potential of the drug to affect fertility adversely have not been performed.","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:43:16.790580+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:44:28.730681+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:54:24.216094+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku AE extraction","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:25:17.941318+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:54:24.216074+00:00"},"safety.specialPopulations":{"url":"","method":"deterministic","source":"FDA Label (special populations)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:43:58.806026+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:44:28.730661+00:00"}},"allNames":"dobutamine hydrochloride in dextrose 5% in plastic container","dailyMed":[{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead","setid":"6b17b98b-e06d-42ed-925f-69aa2699dead","title":"DOBUTAMINE HYDROCHLORIDE IN DEXTROSE (DOBUTAMINE HYDROCHLORIDE) INJECTION [BAXTER HEALTHCARE CORPORATION]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6ceb8d3-e46e-f0da-e053-2995a90a8c3c","setid":"c6ceb8d3-e46e-f0da-e053-2995a90a8c3c","title":"DOBUTAMINE HYDROCHLORIDE INJECTION [HF ACQUISITION CO LLC, DBA HEALTHFIRST]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f56a751-5769-4622-9008-e7fef8e54362","setid":"7f56a751-5769-4622-9008-e7fef8e54362","title":"DOBUTAMINE HYDROCHLORIDE IN DEXTROSE (DOBUTAMINE HYDROCHLORIDE) INJECTION [A-S MEDICATION SOLUTIONS]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0882db1-2532-4b80-b753-68f013fe79e7","setid":"a0882db1-2532-4b80-b753-68f013fe79e7","title":"DOBUTAMINE (DOBUTAMINE HYDROCHLORIDE) INJECTION, SOLUTION [PHYSICIANS TOTAL CARE, INC.]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0dd68b3-20af-464d-b3ba-34eb886df6ae","setid":"c0dd68b3-20af-464d-b3ba-34eb886df6ae","title":"DOBUTAMINE HYDROCHLORIDE INJECTION, SOLUTION [PHYSICIANS TOTAL CARE, INC.]"}],"offLabel":[],"synonyms":["dobutamine","dobutamine hydrochloride","dobutamine HCl"],"timeline":[{"date":"1970-01-01","type":"positive","_source":"Wikipedia","milestone":"Development of Dobutamine Hydrochloride","regulator":"none"},{"date":"1993-09-27","type":"positive","_source":"FDA NDA020255","milestone":"FDA ORIG — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1994-02-16","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1996-03-08","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1998-04-30","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"1999-04-21","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2000-06-14","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2001-05-31","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2003-07-24","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2012-03-05","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2013-04-17","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2019-03-27","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2020-12-10","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""},{"date":"2023-09-08","type":"positive","_source":"FDA NDA020255","milestone":"FDA SUPPL — BAXTER HLTHCARE","regulator":"FDA","description":""}],"variants":[{"slug":"dobutamine-hydrochloride-in-dextrose-5-in-plastic-container","route":"","brandName":"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container","description":"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container","formulation":""}],"aiSummary":"Dobutamine Hydrochloride in 5% Dextrose is a direct-acting inotropic agent indicated for short-term parenteral therapy in cardiac decompensation with depressed contractility. Clinical experience is limited to 48 hours of repeated boluses and/or continuous infusions, with onset within 1-2 minutes and a plasma half-life of 2 minutes. Long-term use is not recommended, as controlled trials show cyclic-AMP-dependent inotropes are not safe or effective for chronic congestive heart failure and are associated with increased hospitalization and death risks. The drug is contraindicated in idiopathic hypertrophic subaortic stenosis and hypersensitivity to dobutamine.","brandName":"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container","ecosystem":[{"indication":"Cardiac Decompensation","otherDrugs":[],"globalPrevalence":null},{"indication":"Cardiac Decompensation Post Cardiac Surgery","otherDrugs":[],"globalPrevalence":null},{"indication":"Cardiogenic shock","otherDrugs":[],"globalPrevalence":3200000},{"indication":"Decompensated cardiac failure","otherDrugs":[{"name":"amrinone","slug":"amrinone","company":"Sanofi Aventis Us"},{"name":"dopamine","slug":"dopamine","company":""},{"name":"furosemide","slug":"furosemide","company":"Sanofi Aventis Us"},{"name":"milrinone","slug":"milrinone","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Organic Cardiac Disease","otherDrugs":[],"globalPrevalence":null},{"indication":"Stress echocardiography using dobutamine","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Beta-receptors of the heart","novelty":"Follow-on","targets":[{"gene":"ADRB2","source":"DrugCentral","target":"Beta-2 adrenergic receptor","protein":"Beta-2 adrenergic receptor","isPrimary":true,"activityType":"EC50","activityValue":6.2},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA5A","source":"DrugCentral","target":"Carbonic anhydrase 5A, mitochondrial","protein":"Carbonic anhydrase 5A, mitochondrial"},{"gene":"CA5B","source":"DrugCentral","target":"Carbonic anhydrase 5B, mitochondrial","protein":"Carbonic anhydrase 5B, mitochondrial"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"}],"moaClass":"Adrenergic beta-Agonists","modality":"Direct-acting sympathomimetic","drugClass":"Inotropic agent","explanation":"Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine. In animal studies, dobutamine produces less increase in heart rate and less decrease in peripheral vascular resistance for a given inotropic effect than does isoproterenol.\n\nIn patients with depressed cardiac function, dobutamine increases cardiac output with usually no marked increases in heart rate, and cardiac stroke volume is usually increased. Systemic vascular resistance is usually decreased with administration of dobutamine. Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation.","oneSentence":"Direct-acting inotropic agent stimulating cardiac beta-receptors with mild chronotropic and vasodilative effects.","technicalDetail":"Dobutamine Hydrochloride is a non-selective beta-adrenergic agonist that stimulates the alpha-1D adrenergic receptor, increasing heart rate and contractility through increased cyclic AMP levels and subsequent activation of protein kinase A."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Dobutamine","title":"Dobutamine","extract":"Dobutamine is a medication used in the treatment of cardiogenic shock and severe heart failure. It may also be used in certain types of cardiac stress tests. It is given by IV only, as an injection into a vein or intraosseous as a continuous infusion. The amount of medication needs to be adjusted to the desired effect. Onset of effects is generally seen within 2 minutes. It has a half-life of two minutes. This drug is generally only administered short term, although it may be used for longer periods to relieve symptoms of heart failure in patients awaiting heart transplantation.","wiki_history":"==History==\nIt was developed in the 1970s by Drs. Ronald Tuttle and Jack Mills at Eli Lilly and Company, as a structural analogue of isoprenaline."},"chemblData":{"prodrug":0,"chemblId":"CHEMBL1200418","maxPhase":"4.0","chirality":0,"parenteral":true,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"launchDate":"1978","_launchSource":"DrugCentral (FDA 1978-07-18, )","genericStatus":"Generic — off-patent","manufacturerCount":"1 approved manufacturers"},"fdaRecalls":[],"overdosage":"OVERDOSAGE Overdoses of dobutamine have been reported rarely. The following is provided to serve as a guide if such an overdose is encountered. Signs and Symptoms Toxicity from dobutamine is usually due to excessive cardiac beta-receptor stimulation. The duration of action of dobutamine is generally short (T1/2 = two minutes) because it is rapidly metabolized by catechol-O-methyltransferase. The symptoms of toxicity may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath, and anginal and nonspecific chest pain. The positive inotropic and chronotropic effects of dobutamine on the myocardium may cause hypertension, tachyarrhythmias, myocardial ischemia, and ventricular fibrillation. Hypotension may result from vasodilation. If the product is ingested, unpredictable absorption may occur from the mouth and the gastrointestinal tract. Treatment To obtain up-to-date information about the treatment of overdose, a good resource is your certified Reg","references":[{"id":1,"url":"https://drugcentral.org/drugcard/937","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Dobutamine%20Hydrochloride","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dobutamine Hydrochloride","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Dobutamine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T02:06:06.807034","_validation":{"fieldsValidated":6,"lastValidatedAt":"2026-04-20T08:25:20.653522+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"isoprenaline","drugSlug":"isoprenaline","fdaApproval":"1956-03-09","relationship":"same-class"},{"drugName":"norepinephrine","drugSlug":"norepinephrine","fdaApproval":"1950-07-13","patentExpiry":"Mar 8, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dopamine","drugSlug":"dopamine","fdaApproval":"1974-02-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"phenylephrine","drugSlug":"phenylephrine","fdaApproval":"1952-01-21","patentExpiry":"Sep 26, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"metaraminol","drugSlug":"metaraminol","fdaApproval":"1954-09-29","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methoxamine","drugSlug":"methoxamine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mephentermine","drugSlug":"mephentermine","fdaApproval":"1951-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"midodrine","drugSlug":"midodrine","fdaApproval":"1996-09-06","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenoldopam","drugSlug":"fenoldopam","fdaApproval":"1997-09-23","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"arbutamine","drugSlug":"arbutamine","fdaApproval":"1997-09-12","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"epinephrine","drugSlug":"epinephrine","fdaApproval":"1948-11-19","patentExpiry":"Oct 20, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"droxidopa","drugSlug":"droxidopa","fdaApproval":"2014-02-18","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"dobutamine hydrochloride","howSupplied":"HOW SUPPLIED Dobutamine Hydrochloride in 5% Dextrose Injection in Viaflex Plus plastic containers is available as follows: 2B0791 Dobutamine 250 mg/250 mL NDC 0338-1073-02 2B0792 Dobutamine 500 mg/250 mL NDC 0338-1075-02 2B0793 Dobutamine 1000 mg/250 mL NDC 0338-1077-02 Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product. Directions for use of VIAFLEX PLUS Plastic Container The overwrap is a moisture and oxygen barrier. Do not remove unit from overwrap until ready for use. A sulfur dioxide odor may occur upon removal of the product from the overwrap container. The sulfur dioxide odor from Dobutamine Injection does not pose risk to the clinician or patient using the product. To open Tear overwrap down side at notch and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. Preparation for Administration Visually inspect the container. If the administration port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Caution: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed. 1. Suspend container from eyelet support. 2. Remove plastic protector from administration port at bottom of container. 3. Attach administration set. Refer to complete directions accompanying set. Table 2. Infusion Rate (mL/hr) of Dobutamine Hydrochloride in 5% Dextrose Injection. 1000 mcg/mL Patient's Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110 0.5 0.15 0.30 0.60 0.90 1.2 1.5 1.8 2.1 2.4 2.7 3.0 3.3 1 0.30 0.60 1.2 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 6.6 2.5 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17 5 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33 7.5 2.3 4.5 9.0 14 18 23 27 32 36 41 45 50 10 3.0 6.0 12 18 24 30 36 42 48 54 60 66 12.5 3.8 7.5 15 23 30 38 45 53 60 68 75 83 15 4.5 9.0 18 27 36 45 54 63 72 81 90 99 17.5 5.3 11 21 32 42 53 63 74 84 95 105 116 20 6.0 12 24 36 48 60 72 84 96 108 120 132 2000 mcg/mL Patient's Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110 0.5 0.08 0.15 0.30 0.45 0.60 0.75 0.90 1.1 1.2 1.4 1.5 1.7 1 0.15 0.30 0.60 0.90 1.2 1.5 1.8 2.1 2.4 2.7 3.0 3.3 2.5 0.38 0.75 1.5 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 8.3 5 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17 7.5 1.1 2.3 4.5 6.8 9.0 11 14 16 18 20 23 25 10 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33 12.5 1.9 3.8 7.5 11 15 19 23 26 30 34 38 41 15 2.3 4.5 9.0 14 18 23 27 32 36 41 45 50 17.5 2.6 5.3 11 16 21 26 32 37 42 47 53 58 20 3.0 6.0 12 18 24 30 36 42 48 54 60 66 4000 mcg/mL Patient's Weight (kg) Drug Delivery Rate (mcg/kg/min) 5 10 20 30 40 50 60 70 80 90 100 110 0.5 0.04 0.08 0.15 0.23 0.30 0.38 0.45 0.53 0.60 0.68 0.75 0.83 1 0.08 0.15 0.30 0.45 0.60 0.75 0.90 1.1 1.2 1.4 1.5 1.7 2.5 0.19 0.38 0.75 1.1 1.5 1.9 2.3 2.6 3.0 3.4 3.8 4.1 5 0.38 0.75 1.5 2.3 3.0 3.8 4.5 5.3 6.0 6.8 7.5 8.3 7.5 0.56 1.1 2.3 3.4 4.5 5.6 6.8 7.9 9.0 10 11 12 10 0.75 1.5 3.0 4.5 6.0 7.5 9.0 11 12 14 15 17 12.5 0.94 1.9 3.8 5.6 7.5 9.4 11 13 15 17 19 21 15 1.1 2.3 4.5 6.8 9.0 11 14 16 18 20 23 25 17.5 1.3 2.6 5.3 7.9 11 13 16 18 21 24 26 29 20 1.5 3.0 6.0 9.0 12 15 18 21 24 27 30 33 Baxter, Viaflex and Viaflex Plus are trademarks of Baxter International Inc. or its subsidiaries. Baxter Healthcare Corporation Deerfield, IL 60015 USA Printed in USA 07-19-00-5947 Rev. September 2023","indications":{"approved":[{"name":"Cardiac Decompensation","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures."},{"name":"Cardiac Decompensation Post Cardiac Surgery","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with cardiac decompensation post cardiac surgery."},{"name":"Cardiogenic shock","source":"DrugCentral","snomedId":89138009,"regulator":"FDA","eligibility":"Not specified","prevalenceClass":"1-5 / 10 000","globalPrevalence":3200000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2008[INST])"},{"name":"Decompensated cardiac failure","source":"DrugCentral","snomedId":195111005,"regulator":"FDA","eligibility":"Not specified"},{"name":"Organic Cardiac Disease","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with organic heart disease."},{"name":"Stress echocardiography using dobutamine","source":"DrugCentral","snomedId":703338002,"regulator":"FDA","eligibility":"Not specified"}],"offLabel":[],"pipeline":[]},"isCanonical":true,"_fixedFields":["primaryTarget"],"currentOwner":"Lilly","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"isoprenaline","brandName":"isoprenaline","genericName":"isoprenaline","approvalYear":"1956","relationship":"same-class"},{"drugId":"norepinephrine","brandName":"norepinephrine","genericName":"norepinephrine","approvalYear":"1950","relationship":"same-class"},{"drugId":"dopamine","brandName":"dopamine","genericName":"dopamine","approvalYear":"1974","relationship":"same-class"},{"drugId":"phenylephrine","brandName":"phenylephrine","genericName":"phenylephrine","approvalYear":"1952","relationship":"same-class"},{"drugId":"metaraminol","brandName":"metaraminol","genericName":"metaraminol","approvalYear":"1954","relationship":"same-class"},{"drugId":"methoxamine","brandName":"methoxamine","genericName":"methoxamine","approvalYear":"","relationship":"same-class"},{"drugId":"mephentermine","brandName":"mephentermine","genericName":"mephentermine","approvalYear":"1951","relationship":"same-class"},{"drugId":"midodrine","brandName":"midodrine","genericName":"midodrine","approvalYear":"1996","relationship":"same-class"},{"drugId":"fenoldopam","brandName":"fenoldopam","genericName":"fenoldopam","approvalYear":"1997","relationship":"same-class"},{"drugId":"arbutamine","brandName":"arbutamine","genericName":"arbutamine","approvalYear":"1997","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020255s020lbl.pdf","date":"2026-04-07","type":"news","title":"DOBUTamine Hydrochloride in 5% Dextrose Injection in Plastic Container","source":"www.accessdata.fda.gov"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/020255s014ltr.pdf","date":"2026-04-07","type":"news","title":"Dobutamine HCl in 5% Dextrose Injection, USP in plastic ...","source":"www.accessdata.fda.gov"},{"url":"https://www.datainsightsmarket.com/reports/dobutamine-hydrochloride-drug-1165847","date":"2026-04-07","type":"news","title":"Dobutamine Hydrochloride Drug XX CAGR Growth Outlook 2026 ...","source":"www.datainsightsmarket.com"},{"url":"https://theraradar.com/drugs/dobutamine-hydrochloride-in-dextrose-5-in-plastic-container","date":"2026-04-07","type":"news","title":"dobutamine hydrochloride in dextrose 5% in plastic container","source":"theraradar.com"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020255Orig1s016ltr.pdf","date":"2026-04-07","type":"news","title":"[PDF] Dobutamine HCl in 5% Dextrose Injection, USP in plastic container.","source":"www.accessdata.fda.gov"}],"manufacturing":[{"role":"Manufacturer","site":"Baxter Healthcare Corporation","location":"","operator":"Baxter Healthcare Corporation"}],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Dobutamine"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"DOBUTAMINE HYDROCHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Dobutamine Hydrochloride in Dextrose"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Dobutamine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"DOBUTAMINE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Dobutamine Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Dobutamine in Dextrose"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"DOBUTAMINE"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Dobutamine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147822","MMSL":"2871","NDDF":"000614","UNII":"3S12J47372","VUID":"4019730","CHEBI":"CHEBI:4670","VANDF":"4017541","INN_ID":"3340","RXNORM":"203121","UMLSCUI":"C0012963","chemblId":"CHEMBL1200418","ChEMBL_ID":"CHEMBL926","KEGG_DRUG":"D00632","DRUGBANK_ID":"DB00841","PDB_CHEM_ID":" Y00","PUBCHEM_CID":"36811","SNOMEDCT_US":"26523005","IUPHAR_LIGAND_ID":"535","SECONDARY_CAS_RN":"49745-95-1","MESH_DESCRIPTOR_UI":"D004280"},"drugDescription":{"pH":"3.5 (2.5 to 5.5)","structure":"Structural formulas are provided but not described in text.","appearance":"Not explicitly described in the text.","composition":"Dobutamine Hydrochloride, USP and Dextrose, USP in Water for Injection, USP. Approximately 5 mEq/L sodium bisulfite is added as a stabilizer.","molecularWeight":"","molecularFormula":"(±)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride (Dobutamine Hydrochloride, USP); D-Glucopyranose monohydrate (Dextrose Hydrous, USP)"},"formularyStatus":[],"_enricherVersion":"v2","chemblMechanisms":[{"actionType":"AGONIST","targetChemblId":"CHEMBL213","mechanismComment":null,"mechanismOfAction":"Beta-1 adrenergic receptor agonist"},{"actionType":"AGONIST","targetChemblId":"CHEMBL210","mechanismComment":null,"mechanismOfAction":"Beta-2 adrenergic receptor agonist"}],"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Eli Lilly","relationship":"Current Owner"}],"pharmacokinetics":{"tmax":"One to two minutes onset; up to ten minutes for peak effect","halfLife":"Two minutes","clearance":"","excretion":"Major excretion products in human urine are conjugates of dobutamine and 3-O-methyl dobutamine","metabolism":"Methylation of the catechol and conjugation","proteinBinding":"","bioavailability":"","volumeOfDistribution":""},"publicationCount":73,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01CA07","allCodes":["C01CA07"]},"biosimilarFilings":[],"faersTotalReports":1225,"commercialAnalysis":{"text":"Dobutamine Hydrochloride, marketed by Pfizer Inc., is a synthetic catecholamine used to treat cardiac decompensation, cardiogenic shock, and decompensated cardiac failure [1]. The drug's revenue trajectory is not explicitly stated in the provided sources, but it is marketed and widely used in the pharmaceutical industry.\n\nThe competitive landscape for Dobutamine Hydrochloride is relatively stable, with no imminent patent cliffs or label expansions mentioned in the sources. However, the pipeline for similar drugs is active, with competitors such as milrinone and levosimendan vying for market share [2]. The market for Dobutamine Hydrochloride is expected to grow, with a compound annual growth rate (CAGR) of 4.5% from 2026 to 2034, driven by increasing demand for cardiac medications [3].\n\nKey upcoming catalysts for Dobutamine Hydrochloride include the potential for label expansions and the introduction of new formulations. In 2009, Baxter Healthcare Corporation submitted a supplemental new drug application (sNDA) for Dobutamine HCl in 5% Dextrose Injection, USP in plastic container, which was approved by the FDA [4]. This approval may lead to increased market share and revenue for the drug.\n\nIn conclusion, Dobutamine Hydrochloride is a well-established medication with a stable market position. While the competitive landscape is relatively stable, the pipeline for similar drugs is active, and the market is expected to grow. Key upcoming catalysts, such as label expansions and new formulations, may drive revenue growth for the drug.\n\nReferences:\n[1] www.accessdata.fda.gov (Dobutamine Hydrochloride in 5% Dextrose Injection in Plastic Container)\n[2] www.accessdata.fda.gov (Dobutamine HCl in 5% Dextrose Injection, USP in plastic ...)\n[3] www.datainsightsmarket.com (Dobutamine Hydrochloride Drug XX CAGR Growth Outlook 2026-2034)\n[4] www.accessdata.fda.gov (Dobutamine HCl in 5% Dextrose Injection, USP in plastic ...)","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020255s020lbl.pdf","date":"","title":"DOBUTamine Hydrochloride in 5% Dextrose Injection in Plastic Container","source":"www.accessdata.fda.gov"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/020255s014ltr.pdf","date":"","title":"Dobutamine HCl in 5% Dextrose Injection, USP in plastic ...","source":"www.accessdata.fda.gov"},{"url":"https://www.datainsightsmarket.com/reports/dobutamine-hydrochloride-drug-1165847","date":"","title":"Dobutamine Hydrochloride Drug XX CAGR Growth Outlook 2026 ...","source":"www.datainsightsmarket.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"faersReportsByYear":[{"time":"20040206","count":1},{"time":"20040304","count":1},{"time":"20040428","count":1},{"time":"20040503","count":1},{"time":"20040701","count":1},{"time":"20040709","count":1},{"time":"20041201","count":2},{"time":"20050207","count":1},{"time":"20070112","count":1},{"time":"20070614","count":3},{"time":"20070705","count":1},{"time":"20070713","count":1},{"time":"20070806","count":1},{"time":"20070808","count":1},{"time":"20070822","count":1},{"time":"20070823","count":1},{"time":"20071227","count":1},{"time":"20080204","count":1},{"time":"20080220","count":1},{"time":"20080222","count":1},{"time":"20080418","count":1},{"time":"20080422","count":1},{"time":"20080505","count":1},{"time":"20080513","count":1},{"time":"20080611","count":1},{"time":"20080618","count":1},{"time":"20080702","count":1},{"time":"20080711","count":1},{"time":"20080822","count":2},{"time":"20081003","count":2},{"time":"20081030","count":1},{"time":"20081201","count":1},{"time":"20081205","count":1},{"time":"20090402","count":2},{"time":"20090616","count":3},{"time":"20090622","count":1},{"time":"20090624","count":1},{"time":"20090715","count":1},{"time":"20090721","count":1},{"time":"20090914","count":1},{"time":"20091021","count":1},{"time":"20091119","count":1},{"time":"20091202","count":1},{"time":"20091210","count":1},{"time":"20100107","count":1},{"time":"20100122","count":1},{"time":"20100216","count":1},{"time":"20100217","count":1},{"time":"20100304","count":2},{"time":"20100308","count":1},{"time":"20100315","count":1},{"time":"20100317","count":1},{"time":"20100407","count":1},{"time":"20100427","count":1},{"time":"20100504","count":1},{"time":"20100521","count":2},{"time":"20100528","count":1},{"time":"20100713","count":1},{"time":"20100715","count":1},{"time":"20100721","count":1},{"time":"20100921","count":1},{"time":"20101004","count":1},{"time":"20101007","count":1},{"time":"20101013","count":1},{"time":"20101014","count":3},{"time":"20101019","count":1},{"time":"20101110","count":1},{"time":"20101116","count":1},{"time":"20101206","count":1},{"time":"20110114","count":1},{"time":"20110314","count":1},{"time":"20110404","count":1},{"time":"20110407","count":2},{"time":"20110412","count":1},{"time":"20110427","count":2},{"time":"20110429","count":2},{"time":"20110502","count":7},{"time":"20110505","count":1},{"time":"20110506","count":2},{"time":"20110509","count":1},{"time":"20110510","count":1},{"time":"20110511","count":1},{"time":"20110512","count":5},{"time":"20110513","count":3},{"time":"20110516","count":2},{"time":"20110517","count":3},{"time":"20110518","count":2},{"time":"20110519","count":6},{"time":"20110520","count":5},{"time":"20110523","count":1},{"time":"20110524","count":8},{"time":"20110525","count":6},{"time":"20110526","count":2},{"time":"20110527","count":2},{"time":"20110531","count":7},{"time":"20110601","count":1},{"time":"20110602","count":1},{"time":"20110603","count":4},{"time":"20110606","count":2},{"time":"20110607","count":6},{"time":"20110608","count":4},{"time":"20110609","count":1},{"time":"20110610","count":3},{"time":"20110615","count":3},{"time":"20110616","count":4},{"time":"20110617","count":1},{"time":"20110713","count":1},{"time":"20110714","count":1},{"time":"20110916","count":1},{"time":"20120103","count":4},{"time":"20120131","count":1},{"time":"20120202","count":1},{"time":"20120227","count":1},{"time":"20120615","count":1},{"time":"20120619","count":1},{"time":"20120626","count":1},{"time":"20120702","count":1},{"time":"20120703","count":1},{"time":"20120705","count":1},{"time":"20120713","count":1},{"time":"20120831","count":1},{"time":"20120914","count":1},{"time":"20120918","count":1},{"time":"20120924","count":1},{"time":"20121207","count":1},{"time":"20121213","count":1},{"time":"20121228","count":1},{"time":"20130110","count":1},{"time":"20130205","count":1},{"time":"20130207","count":1},{"time":"20130208","count":1},{"time":"20130213","count":1},{"time":"20130218","count":1},{"time":"20130315","count":1},{"time":"20130321","count":13},{"time":"20130326","count":1},{"time":"20130329","count":1},{"time":"20130402","count":1},{"time":"20130426","count":1},{"time":"20130509","count":1},{"time":"20130517","count":1},{"time":"20130614","count":1},{"time":"20130701","count":2},{"time":"20130725","count":1},{"time":"20130906","count":1},{"time":"20130911","count":1},{"time":"20130912","count":1},{"time":"20130924","count":1},{"time":"20131029","count":1},{"time":"20140113","count":1},{"time":"20140423","count":2},{"time":"20140528","count":1},{"time":"20140618","count":1},{"time":"20140804","count":1},{"time":"20140826","count":1},{"time":"20140904","count":1},{"time":"20140908","count":1},{"time":"20140911","count":1},{"time":"20140919","count":30},{"time":"20140926","count":1},{"time":"20141010","count":1},{"time":"20141107","count":1},{"time":"20141111","count":2},{"time":"20141126","count":1},{"time":"20141210","count":1},{"time":"20141231","count":1},{"time":"20150113","count":1},{"time":"20150116","count":4},{"time":"20150130","count":1},{"time":"20150212","count":1},{"time":"20150220","count":1},{"time":"20150415","count":1},{"time":"20150429","count":1},{"time":"20150512","count":1},{"time":"20150526","count":1},{"time":"20150625","count":155},{"time":"20150630","count":1},{"time":"20150709","count":1},{"time":"20150713","count":1},{"time":"20150716","count":1},{"time":"20150722","count":1},{"time":"20150730","count":4},{"time":"20150810","count":1},{"time":"20150811","count":1},{"time":"20150814","count":1},{"time":"20150819","count":1},{"time":"20150915","count":1},{"time":"20150916","count":2},{"time":"20150930","count":1},{"time":"20151019","count":1},{"time":"20151020","count":1},{"time":"20151207","count":7},{"time":"20151216","count":1},{"time":"20151223","count":1},{"time":"20151228","count":1},{"time":"20160111","count":2},{"time":"20160122","count":1},{"time":"20160217","count":1},{"time":"20160304","count":1},{"time":"20160309","count":1},{"time":"20160401","count":1},{"time":"20160406","count":1},{"time":"20160408","count":1},{"time":"20160414","count":2},{"time":"20160420","count":1},{"time":"20160428","count":2},{"time":"20160511","count":2},{"time":"20160513","count":1},{"time":"20160607","count":1},{"time":"20160608","count":1},{"time":"20160709","count":2},{"time":"20160715","count":1},{"time":"20160726","count":1},{"time":"20160808","count":1},{"time":"20161117","count":1},{"time":"20161124","count":3},{"time":"20161202","count":1},{"time":"20170222","count":1},{"time":"20170328","count":73},{"time":"20170418","count":1},{"time":"20170419","count":1},{"time":"20170531","count":1},{"time":"20170612","count":1},{"time":"20170804","count":1},{"time":"20170821","count":1},{"time":"20170824","count":1},{"time":"20170908","count":1},{"time":"20170915","count":1},{"time":"20170922","count":1},{"time":"20171222","count":1},{"time":"20180201","count":1},{"time":"20180202","count":1},{"time":"20180208","count":1},{"time":"20180307","count":1},{"time":"20180323","count":1},{"time":"20180813","count":1},{"time":"20180814","count":1},{"time":"20180815","count":1},{"time":"20180830","count":1},{"time":"20180910","count":1},{"time":"20181009","count":1},{"time":"20181010","count":1},{"time":"20181017","count":1},{"time":"20181108","count":1},{"time":"20181115","count":1},{"time":"20181207","count":1},{"time":"20181217","count":79},{"time":"20190122","count":1},{"time":"20190131","count":1},{"time":"20190211","count":1},{"time":"20190212","count":1},{"time":"20190215","count":1},{"time":"20190501","count":1},{"time":"20190507","count":2},{"time":"20190705","count":1},{"time":"20190726","count":1},{"time":"20190814","count":1},{"time":"20190815","count":1},{"time":"20190911","count":1},{"time":"20190913","count":1},{"time":"20191008","count":1},{"time":"20191019","count":1},{"time":"20191118","count":1},{"time":"20191123","count":1},{"time":"20191126","count":1},{"time":"20191128","count":3},{"time":"20191203","count":1},{"time":"20191206","count":1},{"time":"20200121","count":1},{"time":"20200130","count":1},{"time":"20200131","count":1},{"time":"20200210","count":1},{"time":"20200402","count":1},{"time":"20200408","count":1},{"time":"20200416","count":1},{"time":"20200427","count":2},{"time":"20200713","count":1},{"time":"20200717","count":1},{"time":"20200727","count":1},{"time":"20200905","count":1},{"time":"20200921","count":1},{"time":"20201005","count":1},{"time":"20201009","count":1},{"time":"20201015","count":1},{"time":"20201029","count":1},{"time":"20201030","count":2},{"time":"20201113","count":1},{"time":"20201117","count":1},{"time":"20201208","count":1},{"time":"20201209","count":1},{"time":"20201210","count":1},{"time":"20201215","count":1},{"time":"20201228","count":1},{"time":"20210105","count":1},{"time":"20210106","count":1},{"time":"20210118","count":2},{"time":"20210120","count":1},{"time":"20210121","count":1},{"time":"20210129","count":1},{"time":"20210203","count":1},{"time":"20210210","count":1},{"time":"20210213","count":1},{"time":"20210223","count":2},{"time":"20210224","count":1},{"time":"20210301","count":1},{"time":"20210304","count":1},{"time":"20210307","count":1},{"time":"20210308","count":1},{"time":"20210310","count":1},{"time":"20210325","count":1},{"time":"20210330","count":1},{"time":"20210405","count":1},{"time":"20210407","count":1},{"time":"20210413","count":1},{"time":"20210419","count":1},{"time":"20210421","count":1},{"time":"20210422","count":1},{"time":"20210429","count":2},{"time":"20210506","count":1},{"time":"20210513","count":2},{"time":"20210519","count":1},{"time":"20210521","count":1},{"time":"20210528","count":2},{"time":"20210608","count":1},{"time":"20210616","count":1},{"time":"20210713","count":1},{"time":"20210716","count":1},{"time":"20210720","count":1},{"time":"20210721","count":1},{"time":"20210729","count":2},{"time":"20210730","count":1},{"time":"20210809","count":1},{"time":"20210812","count":1},{"time":"20210814","count":1},{"time":"20210816","count":1},{"time":"20210818","count":1},{"time":"20210819","count":1},{"time":"20210820","count":1},{"time":"20210831","count":1},{"time":"20210904","count":1},{"time":"20210906","count":1},{"time":"20210908","count":1},{"time":"20210909","count":1},{"time":"20210914","count":1},{"time":"20210920","count":2},{"time":"20210924","count":1},{"time":"20210929","count":1},{"time":"20210930","count":1},{"time":"20211001","count":1},{"time":"20211006","count":1},{"time":"20211012","count":1},{"time":"20211015","count":1},{"time":"20211018","count":1},{"time":"20211019","count":2},{"time":"20211020","count":1},{"time":"20211022","count":4},{"time":"20211025","count":1},{"time":"20211026","count":1},{"time":"20211109","count":1},{"time":"20211118","count":1},{"time":"20211119","count":1},{"time":"20211125","count":1},{"time":"20211201","count":2},{"time":"20211207","count":1},{"time":"20211221","count":1},{"time":"20211227","count":1},{"time":"20220120","count":2},{"time":"20220126","count":1},{"time":"20220127","count":2},{"time":"20220203","count":1},{"time":"20220204","count":1},{"time":"20220207","count":1},{"time":"20220209","count":1},{"time":"20220211","count":1},{"time":"20220216","count":1},{"time":"20220223","count":1},{"time":"20220225","count":1},{"time":"20220228","count":1},{"time":"20220302","count":1},{"time":"20220303","count":2},{"time":"20220304","count":1},{"time":"20220309","count":1},{"time":"20220311","count":1},{"time":"20220312","count":1},{"time":"20220317","count":1},{"time":"20220321","count":1},{"time":"20220404","count":2},{"time":"20220405","count":1},{"time":"20220407","count":2},{"time":"20220408","count":4},{"time":"20220413","count":1},{"time":"20220418","count":1},{"time":"20220419","count":1},{"time":"20220420","count":1},{"time":"20220429","count":1},{"time":"20220430","count":2},{"time":"20220502","count":2},{"time":"20220505","count":1},{"time":"20220506","count":1},{"time":"20220509","count":2},{"time":"20220513","count":1},{"time":"20220523","count":2},{"time":"20220524","count":1},{"time":"20220530","count":1},{"time":"20220531","count":2},{"time":"20220610","count":1},{"time":"20220613","count":1},{"time":"20220614","count":2},{"time":"20220616","count":1},{"time":"20220622","count":1},{"time":"20220704","count":1},{"time":"20220707","count":1},{"time":"20220802","count":1},{"time":"20220803","count":1},{"time":"20220804","count":1},{"time":"20220805","count":1},{"time":"20220812","count":1},{"time":"20220818","count":1},{"time":"20220828","count":1},{"time":"20220913","count":1},{"time":"20220922","count":1},{"time":"20220930","count":1},{"time":"20221012","count":1},{"time":"20221019","count":1},{"time":"20221021","count":1},{"time":"20221026","count":3},{"time":"20221030","count":1},{"time":"20221101","count":1},{"time":"20221114","count":1},{"time":"20221115","count":1},{"time":"20221118","count":1},{"time":"20221127","count":1},{"time":"20221130","count":1},{"time":"20221201","count":2},{"time":"20221202","count":1},{"time":"20221205","count":1},{"time":"20221208","count":2},{"time":"20221209","count":1},{"time":"20221213","count":2},{"time":"20221220","count":2},{"time":"20221229","count":1},{"time":"20221230","count":1},{"time":"20230103","count":1},{"time":"20230110","count":1},{"time":"20230127","count":1},{"time":"20230131","count":2},{"time":"20230201","count":1},{"time":"20230206","count":1},{"time":"20230207","count":1},{"time":"20230208","count":1},{"time":"20230211","count":1},{"time":"20230214","count":2},{"time":"20230217","count":1},{"time":"20230220","count":1},{"time":"20230221","count":3},{"time":"20230223","count":1},{"time":"20230227","count":1},{"time":"20230228","count":1},{"time":"20230303","count":2},{"time":"20230306","count":1},{"time":"20230316","count":2},{"time":"20230317","count":1},{"time":"20230320","count":1},{"time":"20230321","count":1},{"time":"20230322","count":1},{"time":"20230323","count":1},{"time":"20230327","count":1},{"time":"20230329","count":3},{"time":"20230331","count":3},{"time":"20230401","count":1},{"time":"20230403","count":4},{"time":"20230404","count":1},{"time":"20230406","count":3},{"time":"20230411","count":1},{"time":"20230412","count":3},{"time":"20230413","count":1},{"time":"20230419","count":1},{"time":"20230420","count":1},{"time":"20230424","count":1},{"time":"20230427","count":1},{"time":"20230502","count":1},{"time":"20230504","count":2},{"time":"20230509","count":2},{"time":"20230510","count":1},{"time":"20230515","count":1},{"time":"20230518","count":1},{"time":"20230522","count":1},{"time":"20230523","count":2},{"time":"20230524","count":1},{"time":"20230526","count":1},{"time":"20230529","count":1},{"time":"20230530","count":1},{"time":"20230531","count":1},{"time":"20230602","count":1},{"time":"20230606","count":2},{"time":"20230607","count":1},{"time":"20230608","count":1},{"time":"20230609","count":2},{"time":"20230610","count":1},{"time":"20230612","count":5},{"time":"20230613","count":1},{"time":"20230616","count":2},{"time":"20230617","count":1},{"time":"20230619","count":2},{"time":"20230620","count":2},{"time":"20230621","count":2},{"time":"20230623","count":1},{"time":"20230626","count":1},{"time":"20230627","count":1},{"time":"20230702","count":1},{"time":"20230703","count":1},{"time":"20230704","count":1},{"time":"20230709","count":1},{"time":"20230711","count":1},{"time":"20230807","count":1},{"time":"20230809","count":1},{"time":"20230810","count":1},{"time":"20230811","count":1},{"time":"20230814","count":1},{"time":"20230815","count":1},{"time":"20230816","count":1},{"time":"20230818","count":1},{"time":"20230821","count":1},{"time":"20230823","count":1},{"time":"20230824","count":1},{"time":"20230825","count":3},{"time":"20230828","count":1},{"time":"20230904","count":3},{"time":"20230905","count":1},{"time":"20230906","count":1},{"time":"20230913","count":1},{"time":"20230925","count":6},{"time":"20230926","count":1},{"time":"20231009","count":1},{"time":"20231010","count":1},{"time":"20231017","count":1},{"time":"20231019","count":1},{"time":"20231023","count":4},{"time":"20231025","count":2},{"time":"20231026","count":1},{"time":"20231102","count":1},{"time":"20231103","count":2},{"time":"20231128","count":1},{"time":"20231201","count":1},{"time":"20231208","count":1},{"time":"20231220","count":1},{"time":"20231223","count":1},{"time":"20231227","count":1},{"time":"20231228","count":1},{"time":"20240102","count":1},{"time":"20240103","count":1},{"time":"20240111","count":1},{"time":"20240122","count":1},{"time":"20240123","count":1},{"time":"20240125","count":1},{"time":"20240208","count":1},{"time":"20240213","count":1},{"time":"20240219","count":2},{"time":"20240220","count":1},{"time":"20240227","count":1},{"time":"20240228","count":2},{"time":"20240229","count":2},{"time":"20240304","count":2},{"time":"20240307","count":1},{"time":"20240314","count":1},{"time":"20240324","count":1},{"time":"20240401","count":1},{"time":"20240402","count":1},{"time":"20240405","count":1},{"time":"20240406","count":1},{"time":"20240411","count":1},{"time":"20240417","count":1},{"time":"20240418","count":1},{"time":"20240421","count":1},{"time":"20240424","count":2},{"time":"20240501","count":1},{"time":"20240507","count":1},{"time":"20240510","count":1},{"time":"20240522","count":1},{"time":"20240524","count":1},{"time":"20240528","count":3},{"time":"20240529","count":1},{"time":"20240530","count":1},{"time":"20240614","count":1},{"time":"20240624","count":1},{"time":"20240625","count":1},{"time":"20240708","count":3},{"time":"20240724","count":1},{"time":"20240809","count":1},{"time":"20240811","count":1},{"time":"20240812","count":1},{"time":"20240814","count":1},{"time":"20240820","count":3},{"time":"20240830","count":2},{"time":"20240910","count":1},{"time":"20240925","count":1},{"time":"20240928","count":1},{"time":"20240930","count":1},{"time":"20241004","count":1},{"time":"20241005","count":1},{"time":"20241112","count":1},{"time":"20241118","count":1},{"time":"20241119","count":1},{"time":"20241120","count":1},{"time":"20241205","count":1},{"time":"20241212","count":1},{"time":"20241216","count":1},{"time":"20241219","count":1},{"time":"20241228","count":1},{"time":"20241230","count":1},{"time":"20250104","count":1},{"time":"20250113","count":1},{"time":"20250205","count":2},{"time":"20250210","count":2},{"time":"20250218","count":1},{"time":"20250225","count":2},{"time":"20250306","count":1},{"time":"20250318","count":1},{"time":"20250319","count":1},{"time":"20250324","count":1},{"time":"20250327","count":1},{"time":"20250411","count":1},{"time":"20250603","count":1},{"time":"20250613","count":1},{"time":"20250619","count":1},{"time":"20250623","count":1},{"time":"20250624","count":1},{"time":"20250719","count":1},{"time":"20250728","count":3},{"time":"20250815","count":1},{"time":"20250820","count":1},{"time":"20250828","count":1},{"time":"20250908","count":1},{"time":"20250911","count":1},{"time":"20250924","count":1},{"time":"20250926","count":1},{"time":"20250927","count":1},{"time":"20251009","count":1},{"time":"20251031","count":2},{"time":"20251104","count":1},{"time":"20251119","count":5},{"time":"20251120","count":11},{"time":"20251121","count":3},{"time":"20251124","count":3},{"time":"20251203","count":3},{"time":"20251204","count":3},{"time":"20251208","count":2},{"time":"20251209","count":2},{"time":"20251210","count":2},{"time":"20251219","count":1}],"recentPublications":[{"pmid":"32835622","title":"Possible inhibition mechanism of dobutamine hydrochloride as potent inhibitor for human glucose-6-phosphate dehydrogenase enzyme.","authors":"Kizilbay G, Karaman M","journal":"J Biomol Struct Dyn","pubDate":"2022 Jan"},{"pmid":"27901396","title":"Effects of dobutamine hydrochloride on cardiovascular function in horses anesthetized with isoflurane with or without acepromazine maleate premedication.","authors":"Schier MF, Raisis AL, Secombe CJ, Hosgood G, Musk GC","journal":"Am J Vet Res","pubDate":"2016 Dec"},{"pmid":"25191819","title":"Hydrogen profiles of dobutamine hydrochloride and fentanyl citrate solutions according to intravenous administration systems, temperature, and luminosity conditions.","authors":"Barros DP, Fonseca FL, Pedreira Mda L, Peterlini MA","journal":"J Infus Nurs","pubDate":"2014 Sep-Oct"},{"pmid":"25131356","title":"Effect of intravenous infusion of dobutamine hydrochloride on the development of early postoperative cognitive dysfunction in elderly patients via inhibiting the release of tumor necrosis factor-α.","authors":"Sun D, Yang L, Wu Y, Liu R, Han J","journal":"Eur J Pharmacol","pubDate":"2014 Oct 15"},{"pmid":"23616473","title":"Determination of dobutamine hydrochloride by enzymatic catalytic spectrofluorimetry.","authors":"Tian FS, Chen YH, Liang HY","journal":"Luminescence","pubDate":"2014 Feb"},{"pmid":"19918623","title":"Hydrogen-ion potential of dobutamine hydrochloride solutions exposed to environmental conditions of neonatal intensive care units.","authors":"Reis LL, Peterlini MA, Pedreira ML","journal":"J Pediatr (Rio J)","pubDate":"2009 Nov-Dec"},{"pmid":"17643013","title":"Evaluation of in vitro and in vivo antibacterial activity of dobutamine hydrochloride.","authors":"Sarkar A, Kumar KA, Dutta NK, Chakraborty P, Dastidar SG","journal":"Indian J Med Microbiol","pubDate":"2003 Jul-Sep"},{"pmid":"17472447","title":"Response of hypotensive dogs to dopamine hydrochloride and dobutamine hydrochloride during deep isoflurane anesthesia.","authors":"Rosati M, Dyson DH, Sinclair MD, Sears WC","journal":"Am J Vet Res","pubDate":"2007 May"},{"pmid":"23924599","title":"Stability of Zidovudine and Dobutamine Hydrochloride Injections in 0.9% Sodium Chloride and 5% Dextrose Injections Stored at Ambient Temperature (23 +/- 2 Deg C) and 4 Deg C in 50-mL Polyvinyl Chloride Bags Up to 24 Hours.","authors":"Musami P, Stewart JT, Taylor EW","journal":"Int J Pharm Compd","pubDate":"2004 Jan-Feb"},{"pmid":"12202724","title":"Real-time MR image acquisition during high-dose dobutamine hydrochloride stress for detecting left ventricular wall-motion abnormalities in patients with coronary arterial disease.","authors":"Schalla S, Klein C, Paetsch I, Lehmkuhl H, Bornstedt A","journal":"Radiology","pubDate":"2002 Sep"}],"storageAndHandling":"","participantFlowData":[],"companionDiagnostics":[],"faersSexDistribution":[{"term":1,"count":454},{"term":2,"count":364},{"term":0,"count":14}],"genericManufacturers":10,"_genericFilersChecked":true,"nonclinicalToxicology":"Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to evaluate the carcinogenic or mutagenic potential of dobutamine or the potential of the drug to affect fertility adversely have not been performed.","structuredTrialResults":[],"genericManufacturerList":["Baxter Hlthcare","Dr Reddys","Hikma","Hospira","Luitpold","Slate Run Pharma","Teligent","Teva Parenteral","Watson Labs","Watson Labs Inc"],"faersSeriousnessBreakdown":[{"term":1,"count":1183},{"term":2,"count":42}],"status":"approved","companyName":"Lilly","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1978","enrichmentLevel":5,"visitCount":16,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":10,"withResults":1},"validation":{"fieldsValidated":6,"lastValidatedAt":"2026-04-20T08:25:20.653522+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}